CIBC Private Wealth Group LLC Buys 53,086 Shares of Natera, Inc. $NTRA

CIBC Private Wealth Group LLC raised its stake in Natera, Inc. (NASDAQ:NTRA) by 44.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 173,088 shares of the medical research company’s stock after acquiring an additional 53,086 shares during the period. CIBC Private Wealth Group LLC owned about 0.13% of Natera worth $27,862,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of NTRA. Integrated Wealth Concepts LLC boosted its stake in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after purchasing an additional 96 shares in the last quarter. NewEdge Advisors LLC increased its position in shares of Natera by 68.3% during the 1st quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after purchasing an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its holdings in Natera by 8.6% during the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after purchasing an additional 474 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in Natera in the second quarter valued at about $298,000. Finally, PNC Financial Services Group Inc. boosted its position in Natera by 19.7% in the second quarter. PNC Financial Services Group Inc. now owns 5,033 shares of the medical research company’s stock valued at $850,000 after buying an additional 827 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have weighed in on NTRA. Wells Fargo & Company upped their price objective on shares of Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a research report on Thursday, January 22nd. TD Cowen reaffirmed a “buy” rating on shares of Natera in a report on Wednesday, January 7th. JPMorgan Chase & Co. lifted their price objective on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Morgan Stanley reduced their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Natera has a consensus rating of “Moderate Buy” and a consensus target price of $253.47.

Natera Trading Up 2.5%

Shares of NTRA stock opened at $202.73 on Friday. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $256.36. The firm’s 50 day moving average is $216.05 and its 200-day moving average is $207.05. The firm has a market capitalization of $28.73 billion, a price-to-earnings ratio of -132.50 and a beta of 1.65.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.81. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. The business had revenue of $665.50 million during the quarter, compared to analyst estimates of $600.68 million. During the same quarter last year, the business posted ($0.41) earnings per share. On average, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In other news, insider John Fesko sold 707 shares of Natera stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $204.13, for a total value of $144,319.91. Following the completion of the sale, the insider directly owned 189,199 shares of the company’s stock, valued at approximately $38,621,191.87. This trade represents a 0.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven Leonard Chapman sold 5,623 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $204.13, for a total value of $1,147,822.99. Following the transaction, the chief executive officer directly owned 156,607 shares in the company, valued at $31,968,186.91. This trade represents a 3.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 318,344 shares of company stock valued at $74,091,416 over the last quarter. Corporate insiders own 5.63% of the company’s stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.